Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

The coronavirus disease 2019 (COVID-19) pandemic has demonstrated a clear need for high-throughput, multiplexed and sensitive assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses and their emerging variants. Here, we present a cost-effective virus and variant detection platform, called microfluidic Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (mCARMEN), which combines CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical use. We developed the mCARMEN respiratory virus panel to test for up to 21 viruses, including SARS-CoV-2, other coronaviruses and both influenza strains, and demonstrated its…

• NS
  National Science Foundation

  Award: 1745302
• UD
  U.S. Department of Defense
• HH
  Howard Hughes Medical Institute

  Award: U19AI110818
• UD
  U.S. Department of Homeland Security
• B
  Battelle
• PU
  Princeton University
• MK
  Merck KGaA
• BI
  Broad Institute

  Award: U19AI110818
• OP
  Open Philanthropy Project
• SF
  Skoll Foundation
• RI
  Rhode Island Department of Health
• EF
  ELMA Foundation
• NI
  National Institutes of Health

  Awards: U19AI110818, U01AI151812, COVID-19, T32GM007753
• CF
  Centers for Disease Control and Prevention

  Awards: 75D30120C09605, U19AI110818
• DA
  Defense Advanced Research Projects Agency

  Award: D18AC00006
• AR
  Advanced Research Projects Agency
• NI
  National Institute of General Medical Sciences

  Awards: U19AI110818, T32GM007753
• NI
  National Institute of Allergy and Infectious Diseases

  Awards: COVID-19, U19AI110818, U01AI151812